L3VLUP
ProSign in

NVO · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVOVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVO
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterNVOVRTX
Q3 20207 holders, $2.2bn31 holders, $21.9bn
Q4 20205 holders, $2.0bn30 holders, $18.4bn
Q1 20214 holders, $1.8bn31 holders, $15.4bn
Q2 20215 holders, $2.2bn30 holders, $12.7bn
Q3 20217 holders, $2.4bn35 holders, $10.1bn
Q4 20216 holders, $2.5bn28 holders, $12.4bn
Q1 20227 holders, $2.4bn23 holders, $16.1bn
Q2 202210 holders, $2.5bn25 holders, $18.1bn
Q3 20227 holders, $1.8bn22 holders, $18.4bn
Q4 202212 holders, $3.1bn28 holders, $18.4bn
Q1 202314 holders, $3.8bn26 holders, $21.4bn
Q2 202317 holders, $4.3bn27 holders, $24.7bn
Q3 202320 holders, $5.6bn33 holders, $24.3bn
Q4 202323 holders, $6.0bn32 holders, $28.6bn
Q1 202417 holders, $7.3bn31 holders, $29.8bn
Q2 202424 holders, $8.7bn29 holders, $33.4bn
Q3 202423 holders, $6.5bn27 holders, $33.5bn
Q4 202421 holders, $4.3bn26 holders, $28.5bn
Q1 202518 holders, $2.8bn21 holders, $35.4bn
Q2 202515 holders, $2.4bn21 holders, $32.3bn
Q3 202515 holders, $1.6bn22 holders, $25.9bn
Q4 202512 holders, $1.6bn26 holders, $31.8bn
Q1 202617 holders, $2.9bn25 holders, $31.8bn
Q2 202615 holders, $3.0bn26 holders, $34.6bn
NVO

Novo-nordisk A S

Holders
15
Reported value
$3.0bn
Buyers
13
Sellers
18

Breadth -5 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVO (5)

Dodge & Cox, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Markel Group Inc, Maverick Capital Ltd

Only VRTX (16)

AllianceBernstein LP, AQR Capital Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Citadel Advisors LLC, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Two Sigma Investments LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →